dosage chart tirzepatide Chart: Complete Dosing Schedule and Guidelines The Complete Tirzepatide Dosage Chart

Mean Weight Loss in Pivotal Trials Maximum Dose, ITT Population Tirzepatide 15 mg weekly SURMOUNT-1, NEJM 2022 n=2,539 PMID 35658024 22.5% body weight 72 weeks Tirzepatide 10 mg weekly SURMOUNT-1, NEJM 2022 19.5% body weight 72 weeks Tirzepatide vs Semaglutide head-to-head SURPASS-2, NEJM 2021 n=1,879 +47% more weight loss vs sema Semaglutide 2.4 mg weekly (comparison) STEP-1, NEJM 2021 14.9% body weight 68 weeks Frequently Asked Questions Common questions about NexLife and tirzepatide Is NexLife legit for tirzepatide

Semaglutide, a GLP-1 receptor agonist that has shown remarkable results in clinical studies for weight loss, often outperforms other available therapies

The maximum approved dose produces the greatest weight loss in clinical trials but also the highest side effect incidence

Tirzepatide therapy may not be appropriate for everyone and should never be used without medical supervision